ProShares Ultra NASDAQ Biotechnology
25 hedge funds and large institutions have $5.97M invested in ProShares Ultra NASDAQ Biotechnology in 2019 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 11 closing their positions.
2.49% less ownership
Funds ownership: 6% → 3.51% (-2.5%)
25% less call options, than puts
Call options by funds: $3.2M | Put options by funds: $4.3M
26% less funds holding
Funds holding: 34 → 25 (-9)
57% less capital invested
Capital invested by funds: $13.8M → $5.97M (-$7.79M)
57% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 7
82% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$498K |
| 2 |
Jane Street
New York
|
+$491K |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
+$18K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.83M |
| 2 |
VF
Virtu Financial
New York
|
-$1.59M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$931K |
| 4 |
BRC
Bell Rock Capital
Rehoboth Beach,
Delaware
|
-$678K |
| 5 |
Koshinski Asset Management
Decatur,
Illinois
|
-$263K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
26
Virtu Financial
New York
| – | -$1.59M | -30,676 | Closed |
|
|
27
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$931K | -19,642 | Closed |
|
|
BRC
28
Bell Rock Capital
Rehoboth Beach,
Delaware
| – | -$678K | -13,035 | Closed |
|
|
29
Koshinski Asset Management
Decatur,
Illinois
| – | -$263K | -5,077 | Closed |
|
|
SW
30
SlateStone Wealth
Jupiter,
Florida
| – | -$258K | -4,975 | Closed |
|
|
MC
31
Moors & Cabot
Boston,
Massachusetts
| – | -$207K | -4,000 | Closed |
|
|
CG
32
Cutler Group
San Francisco,
California
| – | -$70K | -1,476 | Closed |
|
33
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$41K | -800 | Closed |
|
|
RCG
34
Ruggie Capital Group
Tavares,
Florida
| – | -$14K | -270 | Closed |
|
35
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$5K | -100 | Closed |
|
BIB Hedge Fund Activity: Q3 2019 in Review
25 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q3 2019, worth a combined $5.97M — down 57% from $13.8M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of BIB and 2 opened new positions — a net loss of 9 holders — while 7 trimmed existing stakes and 3 added.
The largest buyer was HRT Financial, adding an estimated $498K. The largest seller was Tower Research Capital (TRC), cutting an estimated $2.83M.
- 25 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q3 2019, down from 34 in Q2 2019.
- Funds reported $5.97M of ProShares Ultra NASDAQ Biotechnology stock for Q3 2019, down 57% quarter-over-quarter.
- 2 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q3 2019 and 11 closed out, a net change of -9 holders.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q3 2019 was HRT Financial, an estimated $498K added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q3 2019 was Tower Research Capital (TRC), an estimated $2.83M sold.
Based on aggregated 13F filings for Q3 2019.